Who
Robert Baltera Jr.
Director
Company insider
Files Form 4 as: Director, Palisade Bio; Director, Imago BioSciences; Director, Frazier Lifesciences Acquisition; Director, VivoSim Labs; Director, Xencor.
In numbers
- Trades disclosed
- 41
- Buys
- 7
- Sells
- 1
- Bought
- $514K
- Sold
- $24K
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 5 Sep 2012
- Last trade
- 9 Jul 2026
- Last filed
- 10 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jul 2026filed 10 Jul 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Bought | $49K25,000 at $1.96 | filing |
| 9 Jul 2026filed 10 Jul 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Bought | $49K25,000 at $1.96 | filing |
| 8 Jul 2026filed 10 Jul 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Bought | $40K20,000 at $1.99 | filing |
| 8 Jul 2026filed 10 Jul 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Bought | $40K20,000 at $1.99 | filing |
| 7 Jul 2026filed 8 Jul 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Bought | $61K30,000 at $2.03 | filing |
| 7 Jul 2026filed 8 Jul 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Bought | $61K30,000 at $2.03 | filing |
| 6 Jul 2026filed 8 Jul 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Bought | $41K20,000 at $2.05 | filing |
| 6 Jul 2026filed 8 Jul 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Bought | $41K20,000 at $2.05 | filing |
| 2 Jul 2026filed 6 Jul 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Bought | $20K10,000 at $1.98 | filing |
| 2 Jul 2026filed 6 Jul 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Bought | $20K10,000 at $1.98 | filing |
| 1 Jul 2026filed 6 Jul 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Bought | $40K20,000 at $1.98 | filing |
| 1 Jul 2026filed 6 Jul 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Bought | $40K20,000 at $1.98 | filing |
| 10 Jun 2026filed 18 Jun 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Code A | —336,904 | filing |
| 10 Jun 2026filed 18 Jun 2026 | PALI Palisade BioBiotechnology | SEC FORM 4 Code A | —336,904 | filing |
| 11 Jan 2023filed 11 Jan 2023 | Imago BioSciencesoption or derivative | SEC FORM 4 Code D | —114,075 | filing |
| 11 Jan 2023filed 11 Jan 2023 | Imago BioSciencesoption or derivative | SEC FORM 4 Code D | —23,809 | filing |
| 11 Jan 2023filed 11 Jan 2023 | Imago BioSciencesoption or derivative | SEC FORM 4 Code D | —11,904 | filing |
| 11 Jan 2023filed 11 Jan 2023 | Imago BioSciences | SEC FORM 4 Code U | $31K850 at $36.00 | filing |
| 22 Nov 2022filed 23 Nov 2022 | Frazier Lifesciences Acquisitionoption or derivative | SEC FORM 4 Code M | —30,000 | filing |
| 1 Jun 2022filed 3 Jun 2022 | Imago BioSciencesoption or derivative | SEC FORM 4 Code A | —11,904 at $0.00 | filing |
News
GSK (NYSE:GSK) vs. Palisade Bio (NASDAQ:PALI) Financial ReviewPALI · dailypolitical.com · 27 Oct 2026Analyzing Indivior (NASDAQ:INDV) and Palisade Bio (NASDAQ:PALI)PALI · dailypolitical.com · 24 Oct 2026Critical Survey: Nexentis Technologies (NASDAQ:NXTS) versus Palisade Bio (NASDAQ:PALI)PALI · themarketsdaily.com · 24 Oct 2026
0 headlines in the last 90 days name Robert Baltera Jr.; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.